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Abstract
Background: Chronic alveolar hypoxia, due to residence at high altitude or chronic obstructive lung diseases, leads
to pulmonary hypertension, which may be further complicated by right heart failure, increasing morbidity and
mortality. In the non-diseased lung, angiogenesis occurs in chronic hypoxia and may act in a protective, adaptive
manner. To date, little is known about the behaviour of individual vascular endothelial growth factor (VEGF) family
ligands in hypoxia-induced pulmonary angiogenesis. The aim of this study was to examine the expression of
placenta growth factor (PlGF) and VEGFB during the development of hypoxic pulmonary angiogenesis and their
functional effects on the pulmonary endothelium.
Methods: Male Sprague Dawley rats were exposed to conditions of normoxia (21% O2) or hypoxia (10% O2) for
1-21 days. Stereological analysis of vascular structure, real-time PCR analysis of vascular endothelial growth factor A
(VEGFA), VEGFB, placenta growth factor (PlGF), VEGF receptor 1 (VEGFR1) and VEGFR2, immunohistochemistry and
western blots were completed. The effects of VEGF ligands on human pulmonary microvascular endothelial cells
were determined using a wound-healing assay.
Results: Typical vascular remodelling and angiogenesis were observed in the hypoxic lung. PlGF and VEGFB mRNA
expression were significantly increased in the hypoxic lung. Immunohistochemical analysis showed reduced
expression of VEGFB protein in hypoxia although PlGF protein was unchanged. The expression of VEGFA mRNA
and protein was unchanged. In vitro PlGF at high concentration mimicked the wound-healing actions of VEGFA on
pulmonary microvascular endothelial monolayers. Low concentrations of PlGF potentiated the wound-healing
actions of VEGFA while higher concentrations of PlGF were without this effect. VEGFB inhibited the wound-healing
actions of VEGFA while VEGFB and PlGF together were mutually antagonistic.
Conclusions: VEGFB and PlGF can either inhibit or potentiate the actions of VEGFA, depending on their relative
concentrations, which change in the hypoxic lung. Thus their actions in vivo depend on their specific
concentrations within the microenvironment of the alveolar wall during the course of adaptation to pulmonary
hypoxia.
Background
Pulmonary hypertension frequently occurs in people suf-
fering from hypoxic lung diseases such as chronic
obstructive pulmonary disease (COPD), emphysema,
cystic fibrosis and fibrosing alveolitis, often resulting in
right heart failure and increased morbidity and mortality
[1-3]. Such diseases cause tissue destruction within the
airways and gas exchange regions of the lung, accompa-
nied by a loss of the pulmonary vasculature (rarefac-
tion). In addition, sustained vasoconstriction associated
with thickening of the vessel wall results in lumen
reduction that, together with a loss of vessels, results in
increased pulmonary vascular resistance and pulmonary
hypertension (PH).
Chronic alveolar hypoxia is an important mediator of
the development of PH. Hypoxia in the absence of lung
disease causes PH that is associated with arteriolar
remodelling and increased vasoconstriction [4]. In con-
trast to lung disease, hypoxia alone has been shown to
stimulate angiogenesis within the pulmonary circulation,
demonstrating that the adult pulmonary circulation is
capable of increasing the area of its gas exchange region
[4,5]. Such an increase could potentially be beneficial in
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isms underlying this are poorly understood but are of
interest given the therapeutic potential in diseases that
are characterised by vessel loss; e.g. idiopathic pulmon-
ary fibrosis, pulmonary arterial hypertension and
emphysema.
T h e r ei se v i d e n c et os u g g e s tt h a tt h ev a s c u l a r
endothelial growth factor (VEGF) family has a very
important role to play in the development of PH. Expo-
sure to chronic hypoxia, with concurrent blockade of
VEGFR1 and R2, results in a severe and irreversible
form of PH and the development of vascular lesions
similar to those observed in patients with pulmonary
arterial hypertension. Moreover, upon return to a nor-
moxic environment, the disease continues to progress
and is fatal [6-8]. Conversely, overexpression of VEGFA
has been shown to have protective effects in a chronic
hypoxic animal model of PH. This protective effect is
evidenced by a decrease in pulmonary arterial pressure
and RV hypertrophy and a decrease in the percentage of
muscularised arterioles [9]. These results indicate that
vascular endothelial growth factors have an important
role to play in ameliorating the progression of PH. How-
ever, it is currently not known which VEGF ligands are
important or how these ligands interact with each other.
While the role of certain angiogenic growth factors is
well characterised in the systemic circulation, to date lit-
tle is known about the growth factors involved in angio-
genesis within the pulmonary circulation. The VEGF
family of angiogenic ligands, comprised of VEGFA, B, C,
D, E and placenta growth factor (PlGF), are among the
best characterised angiogenic growth factors [10].
VEGFA, B and PlGF have well-established roles in
angiogenesis within the systemic vasculature, while
VEGFC and D are primarily involved in lymphangiogen-
esis [11]. VEGFE, or viral VEGF, is found in several orf
viral strains and pseudocowpox virus but is only
expressed in endothelial cells of pustules following viral
infection [12]. The biological effects of VEGFA, VEGFB
and PlGF are mediated via two specific cell surface-
expressed receptors: VEGFR1 (Flt-1) and VEGFR2 (KDR
or Flk-1). Two co-receptors, neuropilin-1 (NP1) and
neuropilin-2 (NP2), are known to act together with
VEGFR2 to enhance signalling [13]. The system is
further modulated by expression of VEGF splice variants
that are inhibitors of VEGFR signalling [14,15].
To date, little is known of the biological functions of
PlGF in the lung, or indeed of its location within the
lung. Unlike VEGFA, PlGF binds exclusively to
VEGFR1. Because of this exclusive relationship with
VEGFR1, it has been hypothesised that PlGF plays a
role in the angiogenic process by displacing VEGFA
from the R1 “sink”, thereby increasing the fraction of
VEGFA available to bind to VEGFR2, the main
angiogenic pathway [16]. There is also evidence suggest-
ing that PlGF can form a heterodimer with VEGFA
thereby augmenting angiogenesis [17], though this
remains controversial [18]. Recent studies have shown
that PlGF can cause emphysema when over-expressed in
the mouse lung [19], while knocking-out PlGF protected
against the development of elastase-induced emphysema
[20]. Cheng and colleagues [21] have also reported that
PlGF is released from bronchial epithelial cells and
potentially contributes to the development of COPD.
The aim of this study was to examine the expression
profile of the well-established pro-angiogenic VEGF
family members, VEGFA, VEGFB and PlGF, and their
receptors, VEGF R1 and VEGF R2, during the develop-
ment of hypoxic PH. The interactions of VEGFA, VEGFB
and PlGF on human pulmonary microvascular endothe-
lial cells were also investigated in vitro.T h er e s u l t so f
this study show that the interactions between the VEGF
ligands are complex and critically concentration depen-
dent and may exhibit pro- or anti-angiogenic effects.
Methods
Hypoxic Pulmonary Hypertension
All procedures were approved by the University Ethics
Committee and conducted under licence from the
Department of Health. Adult male specific pathogen free
(SPF) Sprague Dawley rats (310-350 g, Harlan, Bicester,
UK) were randomly divided between control and hypoxic
groups. Animals (n = 8) within the hypoxic groups were
exposed to hypoxia (FiO2,0 . 1 0 )f o r1 ,3 ,7 ,1 4a n d
21 days as previously described [4,5,22]. Matched control
animals (n = 8) were maintained in the same room under
normoxic conditions for the same period of time.
Surgical Procedures
Following the exposure period, the animals were
anesthetised (sodium pentobarbitone 70 mg.kg
-¹i n t r a -
peritoneal) and anti-coagulated using heparin (1000 I.U/
kg intravenously) and then killed by exsanguination
[4,5,22]. Following sternotomy, the trachea and pulmon-
ary artery were cannulated and the heart and lungs
removed en bloc. The right main bronchus, the pulmon-
a r ya r t e r ya n dt h ep u l m o n a r yv e i n sw e r et i e dw i t ha
ligature close to the hilum, the right lung removed and
flash frozen.
Left Lung Preparation and Fixation
Normal saline solution (37°C) was perfused through the
p u l m o n a r yv a s c u l a t u r ev i at h ep u l m o n a r ya r t e r yu n t i l
the effluent ran clear. The left lung was then inflated at
as t a n d a r da i r w a yp r e s s u r e( 2 5c m H 2O) with fixative
(4% w/v paraformaldehyde in normal saline solution) via
the trachea. The pulmonary vessels were perfused with
fixative (62.5 cmH2O) and the outflow blocked by a
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constant vascular transmural distending pressure (37.5
cmH2O) during fixation [23].
Following introduction of fixative, the major vessels
and the airway were tied at the hilum and the lung
immersed in fixative for 24 hours and the left lung
volume measured by displacement. Following removal
of the atria, the right ventricular free wall (RV) was dis-
sected from the left ventricle and septum (LV + S) and
each ventricle weighed separately.
Tissue Preparation
The left lung was processed for stereology and immuno-
histochemistry as previously described [24]. Briefly, the
lung was divided into multiple blocks (approximately 2 ×
2 × 4 mm); a systematic randomised sampling strategy
was used to select a subset of blocks for embedding in
resin and preparation of isotropically uniform random
semi-thin (1 micron) sections for stereological analysis.
A second subset of blocks was selected using the systemic
random sampling strategy for embedding in paraffin wax
to prepare sections (5 μm) for immunohistochemistry.
Stereological Protocol for Assessment of Vascular
Parameters
Stereology is a tool that allows quantitative analysis of
three dimensional structures to be undertaken using
two dimensional sections [24]. The stereological analysis
undertaken in this manuscript conforms to the guide-
lines of the Joint Standards for Quantitative Assessment
of Lung Structure, as defined by the American Thoracic
Society and European Respiratory Society joint task
force [25]. In particular, in all lungs the number of
sampled structures of interest (e.g. capillary endothe-
lium, intra-acinar vessels) had a minimum value
between 100 and 200, a sampling intensity that ensures
precise estimates of the measured value (e.g. surface
area, vessel length wall thickness) [26].
Random microscopic images of the lung sections were
selected (x20 objective, Olympus BX61 motorised
microscope,) using a semi-automated Computer
Assisted Stereological Toolbox (CAST) system (Visio-
pharm integrator system version 2.9.11.0; Olympus Den-
mark). These images were digitised (Olympus DP70
digital camera) and displayed on screen to allow stereo-
logical determination of the length density of the vessels
within the gas exchange region of the lung (intra-acinar
vessels), lumen diameter and wall thickness, and capil-
lary endothelial surface area as previously described
[24,27]. Intra-acinar vessels were identified as those
accompanying respiratory bronchioles or more distal
airways and alveoli, which had a diameter greater than
10 μm but less than 100 μm. For assessment of capillary
endothelial surface area, images of tissue were randomly
selected from the tissue section at high magnification
(x100 oil immersion objective). All slides were identified
by code so that the observer was blinded to the experi-
mental conditions in which the rats had been housed.
mRNA Extraction and Real-Time PCR Quantification
mRNA was extracted as previously described [28] and the
expression of genes of interest was quantified using real-
time PCR (TaqMan) performed on duplicate samples.
Probe (labelled with FAM/TAMRA) and primer
sequences were ordered from ABI as Assays-on-Demand
Gene Expression Assays (Table 1). The Eukaryotic 18S
rRNA (VIC/TAMRA) pre-developed assay reagent kit
was used as the endogenous control gene according to
the TaqMan PCR protocol (Applied Biosystems (ABI),
USA). Reactions were carried out on the ABI PRISM
7900 Sequence Detection System and mRNA levels were
determined using the standard curve method (ABI Prism
7700 Sequence Detection System User Bulletin #2).
Immunohistochemistry and Staining Quantification
Tissue sections from 14-day were cleared of wax in xylene
and rehydrated in a series of graded alcohols and immu-
nostained as previously described [29]. The primary anti-
bodies used were anti-human PlGF affinity purified goat
IgG (1:20 dilution, final concentration 10 μg/ml, R&D
Systems, UK) and anti-human VEGFB affinity purified
mouse IgG1 (1:10 dilution, final concentration 50 μg/ml,
R&D Systems, UK). The appropriate biotin labelled sec-
ondary antibodies were used (Biotinylated rabbit anti-goat
IgG, 1:50 dilution, Vector Labs, UK or Biotinylated goat
anti-mouse IgG, 1:50 dilution, Vector Labs, UK) to detect
specific binding using streptavidin-linked horseradish per-
oxidase and diaminobenzidine (Sigma, Ireland). The
volume of tissue stained positively was assessed stereologi-
cally by a blinded reviewer as described and expressed as a
fraction of the total lung volume.
Protein Isolation and Western Blot Analysis
Protein was extracted from control and hypoxic right lungs
and prepared for western blotting as previously described.
Expression of VEGF A protein was assessed using a specific
Table 1 Real Time PCR TaqMan assays. Real-Time PCR
probe and primers name, symbol and ID
Gene Symbol Assay ID
Vascular endothelial growth factor A Vegfa Rn00582935_m1
Vascular endothelial growth factor B Vegfb Rn01454584_g1
Placenta growth factor Pgf Rn00585926_m1
Vascular endothelial growth factor
receptor 1
Vegfr1 Rn00570815_m1
Vascular endothelial growth factor
receptor 2
Vegfr2 Rn00564986_m1
The above probe/primer pairs were obtained from ABI as Assay on Demand.
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endogenous loading control (Abcam).
Scratch Assay Protocol
Endothelial scratch assays were carried out as previously
described [30]. In brief, human pulmonary microvascular
endothelial cells (HMVEC, Lonza, UK) were grown to a
confluent monolayer according to the manufacturer’s
instructions. Following incubation overnight in serum free
medium, a single vertical scratch was applied to each mono-
layer using a sterile pipette tip (S1120-1840, Starlab, UK)
and the medium changed to one containing FBS (3%) plus
growth factor supplements from which VEGFA had been
omitted. After a two-hour “rest” period, the cells were trea-
ted with either vehicle (PBS + 0.1% BSA or 35% acetonitrile
+ 0.1% TFA), or recombinant protein (VEGFA 1-8 ng/ml,
PlGF 10-160 ng/ml or VEGFB 20 ng/ml, R&D Systems, UK)
as appropriate. Images of the scratch (x10 objective, AxioVi-
sion 4.4 software) were used to measure the width of the
wound at 0 and 24 hours. Six to nine separate replicates
were performed for each experiment and all experiments
were performed on cells between Passage 5 and 7.
Statistical Analysis
All statistics were carried out using Statistica 7.0 soft-
ware. Results are expressed as mean ± standard error of
the mean (±SEM). Data were statistically analysed using
a One Way Analysis of Variance (ANOVA) or ANOVA
with repeated measures, followed by a Post-hoc Student
Newman Keul’s test. A value of P < 0.05 was accepted
as statistically significant.
Results
Haematocrit, Right Ventricular Weight and Left Lung
Volume
The mean haematocrit, right ventricular to left ventricle
plus septum (RV to LV+S) weight ratios and the left
lung volumes of control and hypoxic rats following 14
days exposure to chronic hypoxia are shown in Table 2.
An elevation in haematocrit was observed following
hypoxic exposure relative to matched controls, indicat-
ing an increase in red blood cell concentration had
occurred in response to the hypoxic stimulus. The ratio
of RV to LV+S weight was also observed to increase at
14 days of hypoxia relative to matched control values
indicating that prolonged chronic hypoxia produced sig-
nificant RV hypertrophy. Exposure to chronic hypoxia
resulted in a significant increase in lung volume at 14
days of hypoxia. These responses developed progres-
sively at 1, 3, 7 and 21 days (data not shown).
Stereological Quantification of Lung Morphology
Figure 1( A and 1B) shows characteristic images of intra-
acinar blood vessels within (A) control and (B) hypoxic
lungs. An increase in the mean wall thickness was
observed in intra-acinar vessels following exposure to
21 days of hypoxia (figure 1C). A significant increase in
the mean length of small (10 μm-20 μm) intra-acinar
vessels was also observed when compared to matched
controls (figure 1D). The mean total length of intra-aci-
nar blood vessels in hypoxic lungs was greater than that
in control lungs, although this difference was not statis-
tically significant (figure 1E, p = 0.08). Capillary
endothelial surface area was significantly increased fol-
lowing 21 days of exposure to hypoxia (figure 1F).
Vascular Endothelial Growth Factor (VEGF) Ligands and
Receptor mRNA Expression
T h em o s tm a r k e dc h a n g ei nm R N Ae x p r e s s i o nw a s
observed in PlGF, which was significantly augmented in
the hypoxic lung following one week of exposure to
chronic hypoxia and this increase in mRNA expression
was sustained throughout the exposure period (figure 2A).
VEGFB mRNA was also seen to increase significantly at
7 and 14 days; however, this increase was not as persistent
as that of PlGF, as VEGFB mRNA levels were seen to
return to baseline at 21 days (figure 2B). Conversely, expo-
sure to chronic hypoxia did not cause a change in VEGFA
mRNA expression at any time point (figure 2C). VEGF R1
(figure 2D) expression was significantly decreased follow-
ing 21 days exposure to chronic hypoxia while VEGF R2
was not altered at any time point examined (figure 2E).
PlGF and VEGF B Protein Expression in the Rat Lung
Immunohistochemical analysis was performed following
14 days exposure to chronic hypoxia, the time point at
which peak mRNA expression of PlGF and VEGFB were
observed. Figure 3 shows images of PlGF staining in
control (figure 3A-C) and hypoxic (figure 3E-3G) lungs,
with expression being noted in the alveolar wall and
type II pneumocytes (figure 3B and 3F) and the wall of
intra-acinar blood vessels (figure 3Cand 3G). The stain-
ing intensity of PlGF was more intense in some hypoxic
lungs than in control lungs. However, quantitative
stereological analysis of tissue staining positively for
PlGF showed that upon exposure to chronic hypoxia the
fraction of tissue staining for PlGF did not alter (figure
3K). PlGF expression was also observed in macrophages,
Table 2 Haematocrit, Cardiac Ventricular Ratios and Left
Lung Volume in Control and Hypoxic Conditions
Control Hypoxic
Haematocrit (%) 44.8 (1.1) 61.0 (0.4) *
Ventricular Ratio 0.25 (0.01) 0.4 (0.02) *
Left Lung Volume (ml) 3.43 (0.12) 4.14 (0.27) *
Values are mean (±SEM). Ventricular ratio is the ratio between the weight of
the right ventricle and the left ventricle plus septum. * indicates a significant
difference from matched control (P < 0.05, T-Test).
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Page 4 of 13however, it must be noted that not all macrophages
stained positively for PlGF under either experimental
condition (figure 3Iand 3J). PlGF was also found in the
walls of extra-acinar blood vessels and the epithelium of
extra-acinar airways (data not shown).
VEGFB protein was basally expressed in the lung. Figure 4
shows images of VEGFB staining in control (figure 4A-4C)
and hypoxic (figure 4E-4G) lungs, with expression being
noted in the alveolar wall and type II pneumocytes (figure
4Band 4F) and the wall of intra-acinar blood vessels (figure
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Figure 1 Stereological analysis of pulmonary vasculature. Typical images of intra-acinar blood vessels in (A) control and (B) hypoxic lungs.
All images are taken from semi-thin (1-2 μm) sections, are stained with Toluidine Blue and were taken with an x40 objective. Intra-acinar blood
vessels in normoxic lungs were typically thin walled and had little if any medial layer and an internal elastic lamina only. Intra-acinar blood
vessels from hypoxic lungs showed classic vascular remodelling, with the appearance of an external elastic lamina and medial hypertrophy. The
scale bar represents 55 μm. (C) Mean wall thickness (μm) of intra-acinar blood vessels (±SEM) following 21 days exposure to control or hypoxic
conditions. (D) The average length of intra-acinar blood vessel (cm) per diameter category (±SEM) following 21 days exposure to either normoxic
(white circle) or hypoxic (black triangle) conditions. (E) Total intra-acinar blood vessel length was increased in the hypoxic lung, however this
increase failed to reach significance (p = 0.08). (F) Mean capillary endothelium surface area (±SEM, cm
2 per left lung (LL
-1)) following 21 days
exposure to normoxic or hypoxic conditions. * signifies significant difference from matched control (P < 0.05, ANOVA, post-hoc Student
Newman Keuls test). N = 7-8 per group.
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Page 5 of 134Cand 4G). No difference in the staining intensity of
VEGFB was observed in the hypoxic lung. However, stereo-
logical analysis of the volume fraction of positively stained
VEGFB tissue in the lung revealed that upon exposure to
chronic hypoxia, the volume fraction of VEGFB stained cells
was significantly decreased compared to normoxic control
(figure 4K), suggesting reduced total VEGFB expression
within the lung. As with PlGF, expression of VEGFB was
observed in macrophages, however, not all macrophages
stained positively for VEGFB under either control or
hypoxic conditions (figure 4Iand 4J). VEGFB was also found
in the wall of extra-acinar blood vessels and the epithelial
layer of extra-acinar airways (data not shown).
VEGFA protein expression
Western blotting showed that VEGFA protein expres-
sion was not altered in response following 14 days expo-
sure to chronic hypoxia (figure 5).
Role of VEGF Ligands in Endothelial Cell Wound Healing
We next examined the effects of PlGF and VEGFB on pul-
monary microvascular endothelial cell regeneration and
repair using a scratch assay in endothelial cell monolayers.
Since VEGFA is constitutively expressed in the lung and
was unchanged in hypoxia, we compared responses to
both PlGF and VEGFB to those produced by VEGFA and
the interactions of these ligands with VEGFA.
Representative images of normoxic wound healing
assays in the presence of varying concentrations of
recombinant PlGF protein (panels 1-3; vehicle, 40 ng/ml
and 160 ng/ml respectively) are shown in figure 6A.
Increasing concentrations of PlGF (10-80 ng/ml) did not
alter the rate of human microvascular endothelial cell
wound closure compared to vehicle. However, the high-
est concentration of PlGF tested (160 ng/ml) signifi-
cantly increased the rate of wound healing when
compared to vehicle (figure 6B).
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Figure 2 VEGF Ligand mRNA Expression. Mean (± SEM) mRNA expression for (A) PlGF, (B) VEGFB, (C) VEGFA, (D) VEGF Receptor 1 and (E)
VEGF Receptor 2 in control and hypoxic rat lungs. All values are normalised to matched control group. * signifies significant difference from
matched control (P < 0.05, ANOVA, post hoc Student Newman Keuls). N = 6-8 per group.
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Page 6 of 13When administered with VEGFA (8 ng/ml), PlGF
exerted concentration dependent reponses. A low con-
centration of PlGF (40 ng/ml) in combination with
VEGFA significantly increased the rate of wound closure
compared to VEGFA alone (figure 6C). However, addi-
tion of a higher concentration of PlGF (160 ng/ml) to
VEGFA did not significantly increase the rate of wound
closure compared to VEGFA alone (figure 6C).
VEGFB alone did not augment the rate of wound heal-
ing over vehicle. However, VEGFB inhibited the actions of
VEGFA (figure 7A). When PlGF was added to VEGFA and
VEGFB, wound healing was not significantly different
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Figure 3 PlGF protein expression within the rat lung. Images (A-D) are taken from a normoxic lung, while images (E-J) are from a hypoxic
lung. Panels A and E show low magnification images of control and hypoxic tissue. PlGF protein was expressed within the alveolar wall and
type II pneumocytes (black arrows, B and F) and the wall of intra-acinar blood vessels (C and G). Panels (I) and (J) show PlGF stained and
unstained macrophages from the same hypoxic lung (black arrows). A similar pattern of macrophage staining was observed in control lungs (not
shown). Image (D and H) show normoxic (D) and hypoxic (H) lung tissue which was stained with a 1:10 dilution of primary antibody which had
been pre-incubated with recombinant PlGF protein. Pre-incubation of the PlGF antibody with recombinant PlGF protein (R&D, UK) successfully
blocked staining of the tissue therefore indicating that the staining observed is indeed specific for PlGF protein. All images were taken with an
x100 objective, the scale bar represents 20 μm. (K) The volume fraction of PlGF protein was not altered following 14 days exposure to chronic
hypoxia compared to its matched normoxic control. The black bar represents the mean value in each group. N = 7-8 per group.
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Page 7 of 13from VEGFA alone; that is PlGF antagonised the inhibi-
tory effects of VEGFB (figure 7B).
Discussion
We report here for the first time changes in PlGF and
VEGFB expression in the lung in response to hypoxia in
vivo mimicking that found in lung diseases. In addition
we show that VEGFB can inhibit the actions of VEGFA
on pulmonary microvascular endothelial regeneration
and repair. Furthermore, PlGF can counteract the inhi-
bitory effects of VEGFB.
The chronically hypoxic rats reported here showed the
well-documented consequences of such exposure
including right ventricular hypertrophy, elevated haema-
tocrit and increased lung volumes (Table 2), as pre-
viously reported [4,5,28,31-37]. In addition, we observed
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Figure 4 VEGFB protein expression within the rat lung. Images (A-D) are taken from a control lung, while images (E-J) are from a hypoxic
lung. Panels A and E show low magnification images of control and hypoxic tissue. VEGFB protein was expressed within alveolar wall and type
II pneumocytes (black arrows, B and F) and the wall of intra-acinar blood vessels (C and G). Panels (I) and (J) show stained and unstained
macrophages from the same hypoxic lung (black arrows). A similar pattern of macrophage staining was observed in control lungs (not shown).
Images (D) and (H) show control (D) and hypoxic (H) lung tissue to which Isotype matched IgG (mouse IgG1, R&D, UK) was added to the slide
instead of primary antibody. No staining was observed in the IgG slides, therefore indicating that the staining observed is indeed specific for
VEGFB protein. All images were taken with an x100 objective, the scale bar represents 20 μm. (K) The volume fraction of VEGFB protein was
significantly decreased following 14 days exposure to chronic hypoxia compared to its matched normoxic control. The black bar represents the
mean value in each group. * signifies significant difference from matched control (p < 0.05, T-Test, post-hoc Mann Whitney U). N = 7 per group.
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Page 8 of 13increased total length of intra-acinar vessels within the
smallest diameter category (10-20 μm diameter) and
capillary endothelial surface area (indices of angiogen-
esis) that are in keeping with previous reports
[4,5,28,38-40]. The increase in total intra-acinar vessel
length was not statistically significant (P = 0.08), raising
the possibility that the increase in length of small intra-
acinar vessels may have occurred as a result of vessels
“migrating” from larger diameter categories due to wall
remodeling. However, when considered together with
the evidence of capillary angiogenesis in these lungs and
our previous demonstrations of increased intra-acinar
vessel length in response to hypoxia, the data are consis-
tent with new vessel growth [4,5,28]. Characteristic
remodelling of the pulmonary vascular walls was also
observed (figure 1).
Expression of both PlGF and VEGFB mRNA increased
in the hypoxic lung at later time points which corre-
sponded to times at which capillary angiogenesis is
observed in the hypoxic lung [4,5]. Immunohistochemis-
try showed that PlGF protein was expressed in the nor-
mal lung basally and that, although intensity of staining
was increased in some hypoxic lungs, this was not a
consistent finding. Moreover, the proportion of cells
expressing PlGF did not change upon exposure to
chronic hypoxia. Thus there was not a clear increase in
PlGF protein despite the increase in mRNA. Conversely,
immunohistochemical analysis of VEGFB showed that
the proportion of cells expressing this protein was sig-
nificantly reduced in the hypoxic lung (figure 4),
suggesting a reduction in VEGFB protein within the
alveolar wall despite increased VEGFB mRNA.
The finding that VEGFA mRNA expression was not
altered (figure 2) is similar to those of many previous
reports of unaltered mRNA expression [4,36,41-43],
although other reports suggest that VEGFA mRNA
expression is augmented [40,44,45] or VEGFA mRNA is
decreased following 14 days exposure to chronic hypoxia
[46]. Similarly VEGFA protein expression has been
reported as augmented [40,44,45], reduced [46] or
unchanged [47]. We found that VEGFA protein expres-
sion was not altered following 14 days exposure to
chronic hypoxia (figure 5), a finding similar to that of
Engebretsen and colleagues [47]. These apparently dis-
crepant results may arise due to differences in experi-
mental protocols, durations of exposure and species or
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Figure 5 VEGFA protein expression in control and hypoxic rat
lung. Characteristic western blots for VEGFA and GAPDH. There
were no alterations in protein expression of the VEGF ligand in the
hypoxic lung. GAPDH served as a loading control. N = 3 per group.
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Figure 6 The actions of PlGF on endothelial cell wound
healing. (A) Human pulmonary microvascular endothelial cell
scratch assay in the presence of vehicle (panel 1), PlGF (40 ng/ml;
panel 2) and PlGF (160 ng/ml; panel 3). (B) Mean (±SEM) percentage
wound closure over a 24-hour period in the presence of PlGF under
normoxic conditions. (C) Mean (±SEM) percentage wound closure
over a 24-hour period in the presence of VEGFA (8 ng/ml)-PlGF (40
ng/ml) and VEGFA (8 ng/ml)-PlGF (160 ng/ml) in normoxic human
pulmonary microvascular endothelial cells. * signifies a significant
increase in wound healing compared to vehicle, † signifies
significant difference from VEGFA alone (8 ng/ml) (P < 0.05, ANOVA,
post hoc Student Newman Keuls). N = 6-9 per group.
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Page 9 of 13strain differences (e.g. see [47]). Differences in antibo-
dies used may also contribute to the different reports;
given the very extensive homology between different
members of the VEGF family ligands and their many
splice variants, different antibodies may be detecting dif-
ferent proteins from within this large group. The
VEGFA antibody that we used identified a single band
on western blots of rat lungs at a molecular weight
compatible with homodimeric VEGFA165.
Expression of VEGFR1 and VEGFR2 mRNA did not
change substantially in response to hypoxia. However, it
should be noted that the soluble form of VEGFR1,
sVEGFR1 or s-Flt1 may also have been detected by the
TaqMan assay used in this experiment and further work
is required to determine the precise expression of each
individually.
Within the systemic circulation, VEGFA is consis-
tently reported to increase in response to exposure to
chronic hypoxia [48-50], while also being upregulated in
cancer [51-53]. It may at first appear surprising that the
well known pro-angiogenic ligand VEGFA was not
observed to increase in the hypoxic lung given the well
characterised increases in its expression within the
hypoxic systemic circulation. It is important to note that
tumours and ischemic tissues have a PO2 that is much
lower than the PO2 that would ever be encountered
within the hypoxic alveoli. For example, the PO2 of the
alveoli during the development of hypoxic pulmonary
vasoconstriction and pulmonary hypertension is 5.0-8.0
kPa, a value much higher than that of a systemic organ
under conditions of normal oxygenation [54-56]. It is
therefore likely that the mechanisms controlling gene
expression in the two separate circulatory systems are
different [57]. The different control mechanisms and
PO2 could account for the differing expression profiles
encountered in the pulmonary and systemic circulations.
For both PlGF and VEGFB, the changes in protein and
mRNA expression were discordant i.e. mRNA of both
was increased while protein expression remained
unchanged (PlGF) or was reduced (VEGFB). Such dis-
cordance is well recognized in other organs e.g. follow-
ing the onset of skeletal muscle ischaemia VEGF mRNA
is initially elevated but subsequently falls below nor-
moxic values while VEGF protein expression increases
[58]. Differences in mRNA and protein behaviour can
arise by a number of mechanisms e.g. changes in the
rate of translation or modification of the rate of protein
breakdown through post-translational mechanisms.
To gain insight into the functional significance of
VEGFA, VEGFB and PlGF expression, wound healing
assay experiments were conducted in vitro on human
pulmonary microvascular endothelial cells. Although no
changes in the expression profile of VEGFA were
observed, VEGFA is constitutively expressed in the lung;
therefore the actions of PlGF and VEGFB were exam-
i n e db o t hi nt h ep r e s e n c ea n dt h ea b s e n c eo fV E G F A .
The concentration used (8 ng/ml) was chosen as typical
of that required for survival of pulmonary microvascular
endothelial cells in culture. At the lower concentrations
examined (10-80 ng/ml), PlGF did not stimulate wound
healing, a finding similar to those of Cao et al [59] and
Carmeliet et al [60]. However, the highest PlGF concen-
tration tested stimulated wound healing effectively (fig-
ure 6Aand 5B). Given the expression of VEGFA in the
lung, the actions of PlGF in the presence of VEGFA
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Figure 7 VEGF ligand interactions in endothelial cell wound
healing. (A) Mean (±SEM) percentage wound closure over a 24-
hour period in the presence of VEGFA (8 ng/ml), VEGFB (20 ng/ml)
and VEGFA (8 ng/ml)-VEGFB (20 ng/ml). (B) Mean (±SEM)
percentage wound closure over a 24-hour period in the presence of
VEGFA (8 ng/ml), PlGF (40 ng/ml) and VEGFB (20 ng/ml) in
normoxic human pulmonary microvascular endothelial cells. *
signifies a significant increase in wound healing compared to
vehicle, † signifies significant difference from VEGFA (8 ng/ml) (P <
0.05, ANOVA, post hoc Student Newman Keuls). N= 6 per group.
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Page 10 of 13were also examined and showed that PlGF at a low con-
centration augmented wound healing compared to
VEGFA alone (figure 6C), a synergistic effect that has
not previously been recognized. However, when PlGF
was administered at higher concentrations, wound heal-
ing was not increased compared to VEGFA alone (figure
6C) i.e. the synergistic effect was lost. In contrast, these
high concentrations of PlGF when used in the absence
of VEGFA increased the rate of wound healing. Thus
the effects of these two proteins depend critically on
their relative concentrations.
Further insights into the relationship between VEGFA
and PlGF can be obtained by comparing the results of
this study with those of Carmeliet et al [60]. That study
involved administering VEGFA and PlGF to wild-type
capillary endothelial cells and PlGF-/- capillary endothe-
lial cells. They observed that when administered alone
to PlGF-/- cells, the mitogenic and proliferative actions
of VEGFA were greatly reduced compared to wild-type
results. However, when VEGFA was co-administered
with recombinant PlGF to PlGF-/- cells, the degree of
migration and proliferation was similar to wild-type cells
i nt h ep r e s e n c eo fV E G F Aa l o n e. Therefore, Carmeliet
and colleagues surmised that the actions of VEGF-A are
as a result of a degree of synergism with endogenous
PlGF within capillary endothelial cells. The present find-
ing extends the results of Carmeliet and colleagues by
showing that a critical low concentration of PlGF is
required for optimal VEGFA activity, whereas at higher
concentrations this potentiating action is lost.
Our findings provide a potential explanation for the
previously puzzling finding that mice over-expressing
PlGF developed emphysema [19]. It is well established
that loss of VEGFA activity in the lung can result in the
development of emphysema [61]. Excess PlGF expres-
sion in the lung of the transgenic mouse could cause a
loss of synergism between PlGF and VEGFA, similar to
that demonstrated here in vitro, resulting in decreased
VEGFA activity. Furthermore, these findings suggest
that the increased PlGF expression observed in the
serum and BAL fluid of COPD patients could contribute
to the progression of emphysema and COPD [21].
While attractive, this hypothesis will require direct
experimental verification.
Surprisingly, VEGFB was observed to inhibit the wound
healing actions of VEGFA, while having little effect on its
own (figure 7A). It suggests that the reduction in VEGFB
protein that we observed in the lung in vivo would have
augmented VEGFA actions and thus contributed to
hypoxia-induced capillary angiogenesis. To date the role
of VEGFB within the lung has not been fully elucidated.
Investigations of the systemic circulation employing a
VEGFB knockout mouse model showed evidence of cor-
onary vasculature dysfunction [62] but no report of any
abnormalities within the pulmonary circulation. Further
studies have shown a role for VEGFB as a pro-angiogenic
mediator in arthritis induced synovial angiogenesis [63].
However, none of those investigations examined the
interactions of other VEGF ligands with VEGFB.
Since VEGFA, VEGFB and PlGF are all expressed
together, it was of interest to examine the combined
effects of these ligands acting simultaneously. The find-
ing that PlGF and VEGFB antagonise each other when
administered with VEGF-A is an interesting novel find-
ing that emphasises the complex interactions of the
VEGF ligands in the pulmonary circulation (figure 7B).
Conclusions
T h ep r o - a n g i o g e n i cl i g a n d so ft h eV E G Ff a m i l y
(VEGFA, VEGFB and PlGF) have an important homeo-
static role to play within the pulmonary circulation. The
findings reported here demonstrate their differing tem-
poral expression patterns within the hypoxic lung, and
show that they can potentially act as inhibitors of angio-
genic behaviour in pulmonary endothelial cells. Thus
their actions in vivo will depend on their specific con-
centrations within the microenvironment of the alveolar
wall during the course of adaptation to pulmonary
hypoxia.
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